Welcome to our dedicated page for Aura Biosciences SEC filings (Ticker: AURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aura Biosciences, Inc. filings document a clinical-stage biotechnology issuer focused on precision therapies for solid tumors and its common stock listed on The Nasdaq Global Market under AURA. Form 8-K disclosures cover operating and financial results, corporate presentations, executive leadership changes, material agreements, and equity financing activity involving common stock and pre-funded warrants.
Proxy materials describe annual meeting proposals, director elections, auditor ratification, voting results, and board governance. The filing record also includes capital-structure disclosure, risk-factor disclosure, and updates tied to Aura’s clinical pipeline, including bel-sar (AU-011) in ocular oncology and bladder cancer indications.
Aura Biosciences reported new equity awards to director and officer Elisabet de los Pinos. On March 2, 2026, she acquired 166,000 shares of Common Stock through a restricted stock unit award at a grant price of $0.0000 per share, increasing her directly held Common Stock to 575,815 shares.
She also received a stock option for 249,000 shares of Common Stock at an exercise price of $0.0000 per share, with 249,000 option shares outstanding after the award. The RSUs vest in four substantially equal annual installments beginning on January 15, 2027, and the option vests 25% on February 1, 2027, with the remainder vesting pro rata in 36 monthly installments, in each case subject to her continued service.
Separately, 127,763 Common shares are held indirectly by the Elisabet de los Pinos Revocable Trust dated April 8, 2016, of which she is a trustee.
Aura Biosciences Chief Technology Officer Mark Plavsic reported equity grants. He acquired a stock option covering 112,661 shares and 62,339 shares of common stock through a restricted stock unit award.
The RSUs vest in four equal annual installments beginning on January 15, 2027. The option vests 25% on February 1, 2027, with the remaining shares vesting pro rata in 36 monthly installments, in each case contingent on his continued service.
Aura Biosciences reported that Chief Medical Officer Janet Jill Hopkins received new equity awards. She was granted a stock option for 160,944 shares of common stock at an exercise price of $0.00 per share, classified as a grant or award acquisition.
She also acquired 89,056 shares of common stock at $0.00 per share through a restricted stock unit award, bringing her directly held common stock to 321,340 shares after the transaction. The RSUs vest in four substantially equal annual installments beginning on January 15, 2027, conditioned on continued service.
The option vests with 25% of the underlying shares vesting on February 1, 2027, and the remaining 75% vesting pro rata in 36 monthly installments, also subject to her continued service on each vesting date.
Aura Biosciences, Inc. reported that Senior Vice President, Finance, Amy Elazzouzi received new equity awards. She was granted stock options for 80,472 shares at an exercise price of $0.00 and 44,528 shares of common stock via restricted stock units, both as compensation awards.
The restricted stock units vest in four substantially equal annual installments beginning on January 15, 2027, conditioned on continued service. The stock options vest with 25% on February 1, 2027, and the remaining 75% in 36 monthly installments, also subject to continued service.
Aura Biosciences reports amended Schedule 13G/A showing Advent-affiliated entities may beneficially own an aggregate 3.258% of common stock, equal to 2,023,857 shares as of December 31, 2025.
Dr. Rajesh Parekh, a general partner of Advent, is reported with options to purchase 48,000 shares and may be deemed to beneficially own 2,071,857 shares (3.335%) as of December 31, 2025. Each reporting person disclaims beneficial ownership except to the extent of any pecuniary interest.
Aura Biosciences reports a proposed sale of 22,619 shares of common stock. The shares are issuable under a Restricted Stock Unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan on 02/03/2025 and are subject to vesting requirements.
Aura Biosciences reported a Form 144 notice for a proposed sale of common stock. The filing lists 15,890 shares with Morgan Stanley Smith Barney LLC as the broker and a filing date of 02/17/2026. The excerpt also shows restricted stock unit awards of 7,129 (granted 02/01/2024) and 22,619 (granted 02/03/2025).
Aura Biosciences submitted a Form 144 notice relating to Common Stock transactions through Morgan Stanley Smith Barney LLC. The filing records a sale of $92,734.66 for 17,109 shares on 11/17/2025 by Janet Jill Hopkins. The filing also lists restricted stock unit awards of 7,129 (granted 02/01/2024) and 30,159 (granted 02/03/2025) described as subject to vesting requirements.
Amy Elazzouzi reported a sale of 1,581 shares of Common Stock on 01/20/2026. The filing shows Restricted Stock Unit awards of 4,583 granted 02/01/2024 and 11,310 granted 02/03/2025, each described as subject to vesting under the 2021 Stock Option and Incentive Plan.
The broker listed is Morgan Stanley Smith Barney LLC at the address shown, and the filing references Nasdaq with an apparent filing activity date of 02/17/2026.
Aura Biosciences filed a Form 144 reporting a proposed sale of 47,648 shares of Common Stock. The filing lists Morgan Stanley Smith Barney LLC as the broker and Nasdaq as the market. The filing also shows prior insider activity: Elisabet de los Pinos sold 16,928 shares on 01/20/2026 for $82,234.36.